vs

Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and Jerash Holdings (US), Inc. (JRSH). Click either name above to swap in a different company.

Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $41.8M, roughly 1.5× Jerash Holdings (US), Inc.). Jerash Holdings (US), Inc. runs the higher net margin — 2.8% vs -70.9%, a 73.7% gap on every dollar of revenue. On growth, Jerash Holdings (US), Inc. posted the faster year-over-year revenue change (18.0% vs 8.1%). Cytek Biosciences, Inc. produced more free cash flow last quarter ($-1.8M vs $-3.9M). Over the past eight quarters, Jerash Holdings (US), Inc.'s revenue compounded faster (39.1% CAGR vs 17.7%).

Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.

Jerash Holdings (US), Inc. is a global apparel manufacturer producing high-quality outerwear, sportswear, casual and performance apparel for renowned international retail and apparel brand clients. Its core markets cover North America, Europe and Asia Pacific, with manufacturing bases in Jordan and Southeast Asia.

CTKB vs JRSH — Head-to-Head

Bigger by revenue
CTKB
CTKB
1.5× larger
CTKB
$62.1M
$41.8M
JRSH
Growing faster (revenue YoY)
JRSH
JRSH
+9.9% gap
JRSH
18.0%
8.1%
CTKB
Higher net margin
JRSH
JRSH
73.7% more per $
JRSH
2.8%
-70.9%
CTKB
More free cash flow
CTKB
CTKB
$2.1M more FCF
CTKB
$-1.8M
$-3.9M
JRSH
Faster 2-yr revenue CAGR
JRSH
JRSH
Annualised
JRSH
39.1%
17.7%
CTKB

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
CTKB
CTKB
JRSH
JRSH
Revenue
$62.1M
$41.8M
Net Profit
$-44.1M
$1.2M
Gross Margin
52.9%
16.9%
Operating Margin
-9.0%
4.7%
Net Margin
-70.9%
2.8%
Revenue YoY
8.1%
18.0%
Net Profit YoY
-557.1%
20261.5%
EPS (diluted)
$0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTKB
CTKB
JRSH
JRSH
Q4 25
$62.1M
$41.8M
Q3 25
$52.3M
$42.0M
Q2 25
$45.6M
$39.6M
Q1 25
$41.5M
$29.3M
Q4 24
$57.5M
$35.4M
Q3 24
$51.5M
$40.2M
Q2 24
$46.6M
$40.9M
Q1 24
$44.9M
$21.6M
Net Profit
CTKB
CTKB
JRSH
JRSH
Q4 25
$-44.1M
$1.2M
Q3 25
$-5.5M
$461.6K
Q2 25
$-5.6M
$318.7K
Q1 25
$-11.4M
$-152.6K
Q4 24
$9.6M
$-5.8K
Q3 24
$941.0K
$655.3K
Q2 24
$-10.4M
$-1.3M
Q1 24
$-6.2M
$-3.1M
Gross Margin
CTKB
CTKB
JRSH
JRSH
Q4 25
52.9%
16.9%
Q3 25
52.7%
15.0%
Q2 25
52.3%
15.4%
Q1 25
48.6%
17.9%
Q4 24
58.5%
15.2%
Q3 24
56.3%
17.5%
Q2 24
54.6%
11.3%
Q1 24
51.3%
7.0%
Operating Margin
CTKB
CTKB
JRSH
JRSH
Q4 25
-9.0%
4.7%
Q3 25
-17.6%
2.6%
Q2 25
-23.3%
2.4%
Q1 25
-36.1%
1.5%
Q4 24
5.2%
2.0%
Q3 24
-8.2%
2.8%
Q2 24
-18.3%
-2.0%
Q1 24
-23.9%
-14.0%
Net Margin
CTKB
CTKB
JRSH
JRSH
Q4 25
-70.9%
2.8%
Q3 25
-10.5%
1.1%
Q2 25
-12.2%
0.8%
Q1 25
-27.5%
-0.5%
Q4 24
16.8%
-0.0%
Q3 24
1.8%
1.6%
Q2 24
-22.4%
-3.3%
Q1 24
-13.8%
-14.3%
EPS (diluted)
CTKB
CTKB
JRSH
JRSH
Q4 25
$0.09
Q3 25
$0.04
Q2 25
$0.03
Q1 25
$-0.01
Q4 24
$0.00
Q3 24
$0.05
Q2 24
$-0.11
Q1 24
$-0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTKB
CTKB
JRSH
JRSH
Cash + ST InvestmentsLiquidity on hand
$90.9M
$11.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$341.7M
$63.6M
Total Assets
$461.5M
$84.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTKB
CTKB
JRSH
JRSH
Q4 25
$90.9M
$11.5M
Q3 25
$93.3M
$12.0M
Q2 25
$75.5M
$5.8M
Q1 25
$95.3M
$13.3M
Q4 24
$98.7M
$13.2M
Q3 24
$162.3M
$16.3M
Q2 24
$177.9M
$11.4M
Q1 24
$168.8M
$12.4M
Stockholders' Equity
CTKB
CTKB
JRSH
JRSH
Q4 25
$341.7M
$63.6M
Q3 25
$378.6M
$62.8M
Q2 25
$377.6M
$62.7M
Q1 25
$379.6M
$62.8M
Q4 24
$395.7M
$63.1M
Q3 24
$385.5M
$63.4M
Q2 24
$389.1M
$62.9M
Q1 24
$392.6M
$64.4M
Total Assets
CTKB
CTKB
JRSH
JRSH
Q4 25
$461.5M
$84.2M
Q3 25
$494.9M
$83.3M
Q2 25
$493.3M
$81.7M
Q1 25
$482.6M
$83.0M
Q4 24
$499.5M
$79.8M
Q3 24
$491.2M
$80.3M
Q2 24
$483.7M
$76.7M
Q1 24
$492.1M
$80.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTKB
CTKB
JRSH
JRSH
Operating Cash FlowLast quarter
$-771.0K
$-3.8M
Free Cash FlowOCF − Capex
$-1.8M
$-3.9M
FCF MarginFCF / Revenue
-2.9%
-9.3%
Capex IntensityCapex / Revenue
1.6%
0.2%
Cash ConversionOCF / Net Profit
-3.25×
TTM Free Cash FlowTrailing 4 quarters
$-8.8M
$-2.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTKB
CTKB
JRSH
JRSH
Q4 25
$-771.0K
$-3.8M
Q3 25
$-3.9M
$6.8M
Q2 25
$108.0K
$-6.5M
Q1 25
$-125.0K
$1.9M
Q4 24
$2.0M
$-3.0M
Q3 24
$13.2M
$4.6M
Q2 24
$6.2M
$-2.2M
Q1 24
$4.0M
$-5.4M
Free Cash Flow
CTKB
CTKB
JRSH
JRSH
Q4 25
$-1.8M
$-3.9M
Q3 25
$-4.6M
$6.4M
Q2 25
$-1.5M
$-6.9M
Q1 25
$-974.0K
$1.5M
Q4 24
$1.1M
$-3.2M
Q3 24
$12.2M
$4.4M
Q2 24
$5.2M
$-2.3M
Q1 24
$3.4M
$-5.8M
FCF Margin
CTKB
CTKB
JRSH
JRSH
Q4 25
-2.9%
-9.3%
Q3 25
-8.7%
15.3%
Q2 25
-3.2%
-17.5%
Q1 25
-2.3%
5.1%
Q4 24
1.9%
-8.9%
Q3 24
23.7%
11.0%
Q2 24
11.0%
-5.7%
Q1 24
7.6%
-26.9%
Capex Intensity
CTKB
CTKB
JRSH
JRSH
Q4 25
1.6%
0.2%
Q3 25
1.3%
0.9%
Q2 25
3.5%
1.2%
Q1 25
2.0%
1.6%
Q4 24
1.6%
0.4%
Q3 24
2.0%
0.5%
Q2 24
2.3%
0.3%
Q1 24
1.3%
1.9%
Cash Conversion
CTKB
CTKB
JRSH
JRSH
Q4 25
-3.25×
Q3 25
14.72×
Q2 25
-20.33×
Q1 25
Q4 24
0.21×
Q3 24
14.05×
7.06×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTKB
CTKB

Products$46.6M75%
Services$15.5M25%

JRSH
JRSH

Segment breakdown not available.

Related Comparisons